Not provided
Not provided
Not provided
Not provided
Not provided
Interim data and power analysis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this project is to examine the impact of increases in brain insulin on sympathetic nervous system activity, as well as peripheral and cerebral blood flow in humans.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Insulin (Doppler) | Experimental | Human insulin (160 IU) will be administered as a bolus using an intra-nasal device. |
|
| Insulin (MRI) | Experimental | Human insulin (160 IU) will be administered as a bolus using an intra-nasal device. |
|
| Time Control (Doppler) | Other | Time control only |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Carbon dioxide breathing | Other | Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Amount of cerebral blood flow | Measured with trans-cranial Doppler ultrasound (cm/s) or arterial spin labeling (mL/100 g/min) | Change from baseline at minute 15 |
| Measure | Description | Time Frame |
|---|---|---|
| Amount of muscle sympathetic nerve activity (MSNA) | MSNA burst incidence (bursts/100 heart beats) | Change from baseline at minute 15 |
| Amount of leg blood flow | Measured with Doppler ultrasound (mL/min) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Self-reported history of:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jacqueline K Limberg, Ph.D. | University of Missouri-Columbia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Missouri | Columbia | Missouri | 65211 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000783 | Aneurysm |
| D007333 | Insulin Resistance |
| D054969 | Primary Dysautonomias |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069336 | Neurovascular Coupling |
| D007328 | Insulin |
| ID | Term |
|---|---|
| D002560 | Cerebrovascular Circulation |
| D001775 | Blood Circulation |
| D002320 | Cardiovascular Physiological Phenomena |
| D002943 | Circulatory and Respiratory Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Neurovascular Coupling | Other | Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure. |
|
| Human insulin | Drug | Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device. |
|
| Change from baseline at minute 15 |
| D008659 |
| Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D001342 | Autonomic Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011384 | Proinsulin |
| D061385 | Insulins |
| D010187 | Pancreatic Hormones |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |